British Society for Rheumatology Psoriatic Arthritis Register
Research type
Research Study
Full title
The British Society for Rheumatology Psoriatic Arthritis Register (BSR-PsA)
IRAS ID
243288
Contact name
Gareth T Jones
Contact email
Clinicaltrials.gov Identifier
3801, research registry
Duration of Study in the UK
4 years, 1 months, 17 days
Research summary
The British Society for Rheumatology Psoriatic Arthritis Register (BSR‐PsA) is a multi‐centre prospective cohort study of patients with psoriatic arthritis (PsA) who: \n(a)\tAre starting a biologic, biosimilar or targeted synthetic disease‐modifying anti‐rheumatic drug that is been approved or recommended for the treatment of PsA in the United Kingdom, having never previously received that particular agent; or \n(b)\tHave never received one of these medicines. \nThese groups comprise the exposed cohort and comparison cohort, respectively. The study aims to recruit over 1500 patients, questionnaires will be completed by the participants, and clinical data obtained from the rheumatology team and / or the patients’ medical notes. \nParticipants are followed up annually, comprising clinical and questionnaire data. In addition, patients in the exposed cohort will be followed up three and six months after the commencement of that therapy. Questionnaire follow‐up is tied to patients’ anticipated clinical visit schedule, and safety issues, serious adverse events and supplementary information are collected by standardised forms. \nA biobank will be created as part of the study. Participants from the exposed cohort at certain recruiting centres will donate tissue samples (blood and urine) which, alongside the extensive clinical phenotyping, will help facilitate biomarker evaluation and the identification of specific biomolecular predictors of treatment response.
REC name
West of Scotland REC 3
REC reference
18/WS/0126
Date of REC Opinion
15 Aug 2018
REC opinion
Further Information Favourable Opinion